Section Arrow
Quote
SWTX.NASDAQ
- SpringWorks Therapeutics
Quotes are at least 15-min delayed:2025/06/05 13:39 EDT
Last
 46.795
+0.085 (+0.18%)
Day High 
46.8 
Prev. Close
46.71 
1-M High
46.83 
Volume 
2.86M 
Bid
46.79
Ask
46.8
Day Low
46.71 
Open
46.74 
1-M Low
46.05 
Market Cap 
3.52B 
Currency USD 
P/E -- 
%Yield -- 
10-SMA 46.56 
20-SMA 46.38 
50-SMA 43.89 
52-W High 62 
52-W Low 28.21 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-3.41/-2.65
Enterprise Value
3.53B
Balance Sheet
Book Value Per Share
5.54
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
191.59M
Operating Revenue Per Share
--
Industry Comparison
More
Code Name   Last Change Change (%) P/E P/E Range
CLRBCellectar Biosciences0.4273-0.0344-7.45%-- 
NCNANuCana plc0.043-0.0031-6.72%-- 
RXRXRecursion Pharmaceuticals4.705-0.205-4.18%-- 
SCNIScinai Immunotherapeutics Ltd.2.9802+0.4602+18.26%1.21PE
OCGNOcugen0.981174+0.093974+10.59%-- 
Quotes are at least 15-min delayed：2025/06/05 13:39 EDT
Industry overview quotes are at least 15 minutes delayed
Business Description
SpringWorks Therapeutics Inc is a clinical-stage biopharmaceutical company applying a precision medicine approach to acquiring, developing, and commercializing life-changing medicines for underserved patient populations suffering from devastating rare diseases and cancer. The company has a differentiated portfolio of small molecule targeted oncology product candidates and is advancing two potentially registrational clinical trials in rare tumor types, as well as several other programs addressing prevalent, genetically defined cancers. OGSIVEO, the first commercial product, is a novel, oral, selective gamma-secretase inhibitor. GOMEKLI, the second commercial product, is an oral, small molecule mitogen-activated protein kinase, or MEK, inhibitor.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.